Belantamab Mafodotin for Multiple Myeloma | NEJM

38 - Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple MyelomaПодробнее

Daratumumab Plus VRd for Multiple Myeloma | NEJMПодробнее

Final analysis of the DREAMM-2 trial: belantamab mafodotin for R/R multiple myelomaПодробнее

Treatment combinations being explored with belantamab mafodotin in multiple myelomaПодробнее

All About BLENREP (Belantamab Mafodotin-blmf)Подробнее

DREAMM-8: Belantamab mafodotin + pomalidomide and dex shows improved outcomes in RR multiple myelomaПодробнее

The potential role of belantamab mafodotin in multiple myelomaПодробнее

Triplet Therapy, Transplantation, and Maintenance in Myeloma | NEJMПодробнее

The use of belantamab mafodotin in triplet combinations for multiple myelomaПодробнее

DREAMM-5 Study of BLENREP (belantamab mafodotin) Combined with Nirogacestat in RRMM patientsПодробнее

Nivolumab in Advanced Hodgkin’s Lymphoma | NEJMПодробнее

Blenrep (belantamab mafadotin) for multiple myeloma — Dr. Jesus Berdeja | MCRT Webcast August 22Подробнее

A real-world analysis of belantamab mafodotin in patients with R/R multiple myelomaПодробнее

Dr. Richardson on Preliminary Data With Belantamab Mafodotin in Multiple MyelomaПодробнее

An update on the use of belantamab mafodotin in multiple myelomaПодробнее

The safety and efficacy of belantamab mafodotin in R/R multiple myeloma in the real worldПодробнее

Safety and preliminary efficacy of elotuzumab and belantamab mafodotin in patients with R/R myelomaПодробнее

Real-world safety and efficacy of belantamab mafodotin in R/R multiple myelomaПодробнее

DREAMM-3: belantamab mafodotin vs pom/dex for R/R myelomaПодробнее

Dr. Lonial on Data With Belantamab Mafodotin in Multiple MyelomaПодробнее